CymaBay Therapeutics Inc (NASDAQ:CBAY) has received a consensus rating of “Buy” from the fourteen analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $13.89.

Several analysts recently weighed in on CBAY shares. Piper Jaffray Companies set a $29.00 price target on Bausch Health Companies and gave the stock a “buy” rating in a research note on Tuesday, June 11th. Cantor Fitzgerald set a $20.00 price target on CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Sunday, April 14th. Zacks Investment Research downgraded Hess Midstream Partners from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th. ValuEngine upgraded YY from a “sell” rating to a “hold” rating in a research note on Friday, June 7th. Finally, HC Wainwright restated a “neutral” rating on shares of Aerpio Pharmaceuticals in a research note on Wednesday, June 12th.

Shares of CBAY stock traded up $0.28 during midday trading on Monday, reaching $6.50. 588,285 shares of the stock were exchanged, compared to its average volume of 1,000,135. CymaBay Therapeutics has a 1 year low of $4.82 and a 1 year high of $14.00. The company has a 50 day simple moving average of $7.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.66 and a current ratio of 18.66. The firm has a market cap of $427.28 million, a price-to-earnings ratio of -5.16 and a beta of 1.27.

CymaBay Therapeutics (NASDAQ:CBAY) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). As a group, research analysts forecast that CymaBay Therapeutics will post -1.49 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in CBAY. Meeder Asset Management Inc. lifted its position in CymaBay Therapeutics by 307.3% in the 1st quarter. Meeder Asset Management Inc. now owns 2,839 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 2,142 shares in the last quarter. D. E. Shaw & Co. Inc. bought a new position in CymaBay Therapeutics in the 4th quarter valued at approximately $82,000. PNC Financial Services Group Inc. lifted its position in CymaBay Therapeutics by 23.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 13,120 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 2,460 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its position in CymaBay Therapeutics by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 19,900 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 15,542 shares in the last quarter. Finally, Citigroup Inc. lifted its position in CymaBay Therapeutics by 17.7% in the 4th quarter. Citigroup Inc. now owns 19,966 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 3,000 shares in the last quarter. 98.74% of the stock is currently owned by institutional investors and hedge funds.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Read More: Golden Cross

Analyst Recommendations for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.